Cogent Biosciences reported a net loss of $305.2 million for the nine months ended September 30, 2026, compared to $226.4 million in the prior year period, driven by increased R&D and G&A expenses. The company maintained a strong liquidity position with $791.1 million in cash, cash equivalents, and short-term marketable securities as of September 30, 2026.
Cogent Biosciences reported third quarter 2026 financial results and provided a business update, highlighting a cash balance of $791.1 million which is expected to fund operations into late 2028. The company is preparing for the anticipated commercial launch of bezuclastinib in GIST with a PDUFA action date of November 30, 2026, and expects to file INDs for its JAK2 and KRAS pipeline programs in Q4 2026.
“With our commercial team in place, we are prepared to execute on the anticipated launch of bezuclastinib in GIST. In parallel, our team is preparing for potential approvals in NonAdvanced and Advanced Systemic Mastocytosis and we expect to file INDs for our JAK2 and KRAS pipeline programs this quarter. Backed by a strong balance sheet and a world-class team, we are well positioned to continue our vision of creating best-in-class therapies for patients fighting rare, mutationally driven diseases.”
Andrew Robbins, Cogent’s President and Chief Executive Officer